Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
NCT00667810
Last updated date
ABOUT THIS STUDY
This is a study to evaluate the efficacy and safety of multiple doses of bapineuzumab in
patients with mild to moderate Alzheimer Disease. Patients will receive either bapineuzumab
or placebo. Each patient's participation will last approximately 1.5 years.
Study Location
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
By phone
Pfizer Clinical Trials Contact Center
1-800-718-1021
Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Alzheimer Disease
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
Adult Trials: 18+ Years
50-89 years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details
- Diagnosis of probable Alzheimer Disease (AD), with Mini Mental State Examination (MMSE) score of 16-26, and brain magnetic resonance imaging (MRI) consistent with the diagnosis of AD
- Concurrent use of cholinesterase inhibitor or memantine allowed, if stable
- Caregiver will participate and be able to attend clinic visits with patient
Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details
- Significant neurological disease other than AD
- Major psychiatric disorder
- Contraindication to undergo brain MRI [e.g., pacemaker, cerebrospinal fluid (CSF)
shunt, or foreign metal objects in the body]
- Women of childbearing potential
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative
Clinical Trials
Interested in learning more about clinical trials?
Discover how clinical trials work and the impact your participation could have.
TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
Alzheimer DiseaseLipitor as a Treatment for Alzheimer's Disease
NCT00024531
- Sun City, Arizona
ALL GENDERS
50 Years+
years
MULTIPLE SITES
Alzheimer DiseaseStudy Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
NCT00667810
- Birmingham, Alabama
- Goodyear, Arizona
- Phoenix, Arizona
- Phoenix, Arizona
- Phoenix, Arizona
- Phoenix, Arizona
- Little Rock, Arkansas
- Costa Mesa, California
- Encino, California
- Fresno, California
- Laguna Hills, California
- Laguna Hills, California
- Loma Linda, California
- Loma Linda, California
- Long Beach, California
- Los Alamitos, California
- Newport Beach, California
- San Diego, California
- San Diego, California
- San Diego, California
- San Diego, California
- San Diego, California
- San Diego, California
- San Francisco, California
- Boulder, Colorado
- Boulder, Colorado
- Denver, Colorado
- Danbury, Connecticut
- Fairfield, Connecticut
- Greenwich, Connecticut
- Greenwich, Connecticut
- New Haven, Connecticut
- New Haven, Connecticut
- New Haven, Connecticut
- New Haven, Connecticut
- New Haven, Connecticut
- New Haven, Connecticut
- New Haven, Connecticut
- New Haven, Connecticut
- Norwalk, Connecticut
- Waterbury, Connecticut
- Atlantis, Florida
- Atlantis, Florida
- Bradenton, Florida
- Deerfield Beach, Florida
- Delray Beach, Florida
- Fort Lauderdale, Florida
- Hallandale Beach, Florida
- Ocala, Florida
- Ocala, Florida
- Orlando, Florida
- Palm Beach Gardens, Florida
- Port Charlotte, Florida
- Sarasota, Florida
- Sun City, Florida
- Tampa, Florida
- West Palm Beach, Florida
- Atlanta, Georgia
- Columbus, Georgia
- Columbus, Georgia
- Decatur, Georgia
- Decatur, Georgia
- Lawerenceville, Georgia
- Lawrenceville, Georgia
- Elk Grove Village, Illinois
- Elk Grove Village, Illinois
- Peoria, Illinois
- Peoria, Illinois
- Peoria, Illinois
- Peoria, Illinois
- Springfield, Illinois
- Springfield, Illinois
- Elkhart, Indiana
- Mishawaka, Indiana
- Wichita, Kansas
- Wichitia, Kansas
- Paducah, Kentucky
- Paducah, Kentucky
- Lake Charles, Louisiana
- New Orleans, Louisiana
- Shreveport, Louisiana
- Bethesda, Maryland
- Rockville, Maryland
- Boston, Massachusetts
- Boston, Massachusetts
- Boston, Massachusetts
- Boston, Massachusetts
- Boston, Massachusetts
- Boston, Massachusetts
- Boston, Massachusetts
- Haverhill, Massachusetts
- Newton, Massachusetts
- Springfield, Massachusetts
- Ann Arbor, Michigan
- Ann Arbor, Michigan
- Ann Arbor, Michigan
- East Lansing, Michigan
- Lansing, Michigan
- Flowood, Mississippi
- Flowood, Mississippi
- Hattiesburg, Mississippi
- Kansas City, Missouri
- Great Falls, Montana
- Great Falls, Montana
- Berlin, New Jersey
- Eatontown, New Jersey
- Manchester, New Jersey
- Toms River, New Jersey
- Brewster, New York
- Liverpool, New York
- Rochester, New York
- Rochester, New York
- Asheville, North Carolina
- Charlotte, North Carolina
- Hickory, North Carolina
- Hickory, North Carolina
- Raleigh, North Carolina
- Raleigh, North Carolina
- Raleigh, North Carolina
- Raleigh, North Carolina
- Columbus, Ohio
- Columbus, Ohio
- Columbus, Ohio
- Columbus, Ohio
- Toledo, Ohio
- Oklahoma City, Oklahoma
- Oklahoma City, Oklahoma
- Oklahoma City, Oklahoma
- Portland, Oregon
- Abington, Pennsylvania
- Abington, Pennsylvania
- Jenkintown, Pennsylvania
- Philadelphia, Pennsylvania
- Philadelphia, Pennsylvania
- Philadelphia, Pennsylvania
- Philadelphia, Pennsylvania
- Philadelphia, Pennsylvania
- Philadelphia, Pennsylvania
- Pittsburgh, Pennsylvania
- Willow Grove, Pennsylvania
- East Providence, Rhode Island
- Pawtucket, Rhode Island
- Providence, Rhode Island
- Charleston, South Carolina
- Charleston, South Carolina
- Greer, South Carolina
- North Charleston, South Carolina
- Cordova, Tennessee
- Austin, Texas
- Austin, Texas
- Dallas, Texas
- Fort Worth, Texas
- San Antonio, Texas
- San Antonio, Texas
- San Antonio, Texas
- San Antonio, Texas
- Wichita Falls, Texas
- Bennington, Vermont
- Bennington, Vermont
- Charlottesville, Virginia
- Charlottesville, Virginia
- Charlottesville, Virginia
- Bothell, Washington
- Seattle, Washington
- Buenos Aires,
- Buenos Aires,
- Gosford, New South Wales
- Hornsby, New South Wales
- Woodville South, South Australia
- Ballarat, Victoria
- West Heidelberg, Victoria
- Nedlands, Western Australia
- Nedlands, Western Australia
- Adelaide SA,
- Antwerpen,
- Brugge,
- Bruxelles,
- Edegem,
- Leuven,
- Roeselare,
- North York, Ontario
- Ottawa, Ontario
- Toronto, Ontario
- Toronto, Ontario
- L'Ancienne-Lorette, Quebec
- Montreal, Quebec
- Montreal, Quebec
- Sherbrooke, Quebec
- Quebec,
- Santiago,
- Santiago,
- Zagreb,
- Zagreb,
- Kuopio,
- Turku,
- Rennes, Cedex
- Amiens,
- Bron,
- Caen,
- Colmar,
- Dijon,
- Lille,
- Marseille,
- Marseille,
- Montpellier,
- Nantes - Saint Herblain,
- Nice,
- Paris Cedex 13,
- Paris,
- Poitiers,
- Reims,
- Rouen,
- Toulouse,
- Toulouse,
- Berlin,
- Bochum,
- Offenburg,
- Regensburg,
- Ancona,
- Brescia,
- Catania,
- Chieti,
- Firenze,
- Milano,
- Milano,
- Milano,
- Monza,
- Monza,
- Roma,
- Roma,
- Siena,
- Nagoya, Aichi,
- Ota-ku, Tokyo
- Aichi,
- Chiba,
- Chiba,
- Chiba,
- Fukuoka,
- Gunma,
- Gunma,
- Gunma,
- Hiroshima,
- Hyogo,
- Hyogo,
- Hyogo,
- Iwate,
- Kagawa,
- Kanagawa,
- Kanagawa,
- Kanagawa,
- Kyoto,
- Kyoto,
- Kyoto,
- Nagano,
- Niigata,
- Okayama,
- Okayama,
- Osaka,
- Osaka,
- Osaka,
- Shizuoka,
- Tokyo,
- Tokyo,
- Tokyo,
- Tokyo,
- Tokyo,
- Seongnam-si, Gyeonggi-do
- Seoul,
- Monterrey, Nuevo León
- Aguascalientes,
- 's-Hertogenbosch,
- Amsterdam,
- Breda,
- Eindhoven,
- Haarlem,
- Leeuwarden,
- s. Hertogenbosch,
- Auckland, NZ
- Christchurch,
- Bydgoszcz,
- Kielce,
- Krakow,
- Poznan,
- Warszawa,
- Warszawa,
- Amadora,
- Coimbra,
- Lisboa,
- Kazan,
- Nizhny Novgorod,
- Saint-Petersburg,
- Saint-Petersburg,
- Saint-Petersburg,
- Saint-Petersburg,
- Novi Sad, Vojvodina
- Belgrade,
- Beograd,
- Kragujevac,
- Bratislava,
- Bratislava,
- Bratislava,
- Bratislava,
- Martin,
- Michalovce,
- Rimavska Sobota,
- Zilina,
- Johannesburg, Gauteng
- Johannesburg, Gauteng
- Pretoria, Gauteng
- Durban, Kwa Zulu Natal
- Panorama, Western Cape
- Elche, Alicante
- Terrassa, Barcelona
- Plasencia, Caceres
- Palma de Mallorca, Islas Baleares
- Palma de Mallorca, Islas Baleares
- Baracaldo,
- Barcelona,
- Barcelona,
- Barcelona,
- Barcelona,
- Burgos,
- Madrid,
- Madrid,
- Madrid,
- Madrid,
- Madrid,
- Murcia,
- Malmo,
- Uppsala,
- Uppsala,
- Uppsala,
- Basel, BS
- Les Acacias, GE
- Lausanne, VD
- Thonex-Geneva,
- Blackpool, Lancashire
- Bradford, West Yorkshire
- Brighton,
- Glasgow,
- London,
- London,
- Newcastle upon Tyne,
- Northampton,
- Penarth,
- Sheffield,
- Sheffield,
- Swindon,
ALL GENDERS
50 Years+
years
MULTIPLE SITES
Alzheimer DiseaseStudy Evaluating PAZ-417 in Cerebrospinal Fluid in Subjects With Alzheimer's Disease
NCT00739037
- Glendale, California
ALL GENDERS
55 Years+
years
MULTIPLE SITES
Alzheimer DiseaseStudy Evaluating the Safety and Efficacy of Bapineuzumab in Alzheimer Disease Patients
NCT00676143
- Birmingham, Alabama
- Birmingham, Alabama
- Birmingham, Alabama
- Birmingham, Alabama
- Goodyear, Arizona
- Phoenix, Arizona
- Phoenix, Arizona
- Phoenix, Arizona
- Phoenix, Arizona
- Little Rock, Arkansas
- Carson, California
- Long Beach, California
- San Francisco, California
- Boulder, Colorado
- Boulder, Colorado
- Denver, Colorado
- Fairfield, Connecticut
- Greenwich, Connecticut
- Greenwich, Connecticut
- New Haven, Connecticut
- New Haven, Connecticut
- New Haven, Connecticut
- New Haven, Connecticut
- New Haven, Connecticut
- New Haven, Connecticut
- New Haven, Connecticut
- Norwalk, Connecticut
- Atlantis, Florida
- Atlantis, Florida
- Atlantis, Florida
- Delray Beach, Florida
- Orlando, Florida
- Palm Beach Gardens, Florida
- Port Charlotte, Florida
- Sarasota, Florida
- Tampa, Florida
- Decatur, Georgia
- Decatur, Georgia
- Lawrenceville, Georgia
- Elk Grove Village, Illinois
- Springfield, Illinois
- Springfield, Illinois
- Kansas City, Kansas
- Lake Charles, Louisiana
- Boston, Massachusetts
- Boston, Massachusetts
- Boston, Massachusetts
- Boston, Massachusetts
- Boston, Massachusetts
- Boston, Massachusetts
- Boston, Massachusetts
- Dartmouth, Massachusetts
- Pittsfield, Massachusetts
- Springfield, Massachusetts
- Ann Arbor,, Michigan
- Ann Arbor, Michigan
- Ann Arbor, Michigan
- Ann Arbor, Michigan
- East Lansing, Michigan
- Hattiesburg, Mississippi
- Kansas City, Missouri
- Eatontown, New Jersey
- Edison, New Jersey
- Manchester, New Jersey
- Liverpool, New York
- Raleigh, North Carolina
- Raleigh, North Carolina
- Raleigh, North Carolina
- Raleigh, North Carolina
- Columbs, Ohio
- Columbs, Ohio
- Columbus, Ohio
- Portland, Oregon
- Portland, Oregon
- Portland, Oregon
- Portland, Oregon
- Silverton, Oregon
- Abington, Pennsylvania
- Abington, Pennsylvania
- Abington, Pennsylvania
- Flourtown, Pennsylvania
- Jenkintown, Pennsylvania
- Philadelphia, Pennsylvania
- Philadelphia, Pennsylvania
- Philadelphia, Pennsylvania
- Philadelphia, Pennsylvania
- Philadelphia, Pennsylvania
- Philadelphia, Pennsylvania
- Willow Grove, Pennsylvania
- East Providence, Rhode Island
- Pawtucket, Rhode Island
- Providence, Rhode Island
- Charleston, South Carolina
- Charleston, South Carolina
- Charleston, South Carolina
- North Charleston, South Carolina
- Dallas, Texas
- San Antonio, Texas
- San Antonio, Texas
- San Antonio, Texas
- San Antonio, Texas
- San Antonio, Texas
- San Antonio, Texas
- San Antonio, Texas
- Bennington, Vermont
- Bennington, Vermont
- Madison, Wisconsin
- Madison, Wisconsin
- Madison, Wisconsin
- Madison, Wisconsin
- Madison, Wisconsin
- Buenos Aires,
- Buenos Aires,
- Buenos Aires,
- Cordoba,
- Gosford, New South Wales
- Gosford, New South Wales
- Hornsby, New South Wales
- Adelaide, South Australia
- Woodville South, South Australia
- Ballarat, Victoria
- West Heidelberg, Victoria
- Nedlands, Western Australia
- Nedlands, Western Australia
- Graz,
- Klagenfurt,
- Wien,
- Wien,
- Wien,
- Antwerpen,
- Brugge,
- Brussels,
- Edegem,
- Leuven,
- Roeselare,
- Santiago,
- Santiago,
- Zagreb,
- Kuopio,
- Turku,
- Bordeaux Cedex,
- Bron,
- Caen,
- Caen,
- Colmar,
- Dijon,
- Lille,
- Marseille,
- Montpellier,
- Nantes - Saint Herblain,
- Nice,
- Nice,
- Paris,
- Paris,
- Poitiers,
- Reims,
- Rennes Cedex,
- Rouen,
- Toulouse,
- Toulouse,
- Berlin,
- Bochum,
- Dresden,
- Freiburg,
- Offenburg,
- Ulm,
- Ancona,
- Ancona,
- Brescia,
- Catania,
- Catania,
- Chieti,
- Milano,
- Monza,
- Roma,
- Roma,
- Siena,
- Nagoya, Aichi,
- Kiyose, Tokyo
- Aichi,
- Chiba,
- Chiba,
- Chiba,
- Fukuoka,
- Gunma,
- Gunma,
- Gunma,
- Hiroshima,
- Hyogo,
- Hyogo,
- Hyogo,
- Iwate,
- Kagawa,
- Kanagawa,
- Kanagawa,
- Kanagawa,
- Kyoto,
- Kyoto,
- Kyoto,
- Nagano,
- Niigata,
- Okayama,
- Okayama,
- Osaka,
- Osaka,
- Osaka,
- Shizuoka,
- Tokyo,
- Tokyo,
- Tokyo,
- Tokyo,
- Tokyo,
- Monterrey, Nuevo León
- Aguascalientes,
- Breda, Noord Brabant
- Hilversum, Noord Holland
- Haarlem, The Netherlands
- 's-Hertogenbosch,
- Alkmaar,
- Amsterdam,
- Eindhoven,
- Leeuwarden,
- Rotterdam,
- Auckland, NZ
- Christchurch,
- Bydgoszcz,
- Krakow,
- Poznan,
- Warszawa,
- Warszawa,
- Amadora,
- Coimbra,
- Lisboa,
- Belgrade,
- Kragujevac,
- Novi Sad,
- Sremska Kamenica,
- Sremska Kamenica,
- Bratislava,
- Bratislava,
- Michalovce,
- Rimavska Sobota,
- Johannesburg, Gauteng
- Johannesburg, Gauteng
- Pretoria, Gauteng
- Durban, Kwa Zulu Natal
- Bellville, Western Cape
- Panorama, Western Cape
- Elche, Alicante
- Terrassa, Barcelona
- Plasencia, Caceres
- Palma de Mallorca, Islas Baleares
- Palma de Mallorca, Islas Baleares
- San Sebastian, Pais Vasco
- Baracaldo, Vizcalla
- Barcelona,
- Barcelona,
- Barcelona,
- Barcelona,
- Burgos,
- Madrid,
- Madrid,
- Madrid,
- Madrid,
- Madrid,
- Murcia,
- Malmo,
- Uppsala,
- Uppsala,
- Uppsala,
- Basel, BS
- Les Acacias, GE
- Lausanne, VD
- Thonex-Geneva,
- Blackpool, Lancashire
- Trafford Park, Manchester
- Bradford,
- Brighton,
- Glasgow,
- London,
- London,
- Newcastle upon Tyne,
- Northampton,
- Penarth,
- Sheffield,
- Sheffield,
- Swindon,
ALL GENDERS
50 Years+
years
MULTIPLE SITES
Advanced Information
| Descriptive Information | ||||
|---|---|---|---|---|
| Brief Title ICMJE | Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients | |||
| Official Title ICMJE | A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers | |||
| Brief Summary | This is a study to evaluate the efficacy and safety of multiple doses of bapineuzumab in patients with mild to moderate Alzheimer Disease. Patients will receive either bapineuzumab or placebo. Each patient's participation will last approximately 1.5 years. | |||
| Detailed Description | Not Provided | |||
| Study Type ICMJE | Interventional | |||
| Study Phase ICMJE | Phase 3 | |||
| Study Design ICMJE | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) Primary Purpose: Treatment | |||
| Condition ICMJE | Alzheimer Disease | |||
| Intervention ICMJE |
| |||
| Study Arms ICMJE |
| |||
| Publications * |
| |||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | ||||
| Recruitment Information | ||||
| Recruitment Status ICMJE | Terminated | |||
| Actual Enrollment ICMJE | 901 | |||
| Original Estimated Enrollment ICMJE | 1250 | |||
| Actual Study Completion Date ICMJE | August 2013 | |||
| Actual Primary Completion Date | October 2012 (Final data collection date for primary outcome measure) | |||
| Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
| |||
| Sex/Gender ICMJE |
| |||
| Ages ICMJE | 50 Years to 89 Years (Adult, Older Adult) | |||
| Accepts Healthy Volunteers ICMJE | No | |||
| Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | |||
| Listed Location Countries ICMJE | Argentina, Australia, Belgium, Canada, Chile, Croatia, Finland, France, Germany, Italy, Japan, Korea, Republic of, Mexico, Netherlands, New Zealand, Poland, Portugal, Russian Federation, Serbia, Slovakia, South Africa, Spain, Sweden, Switzerland, United Kingdom, United States | |||
| Removed Location Countries | Austria, Czech Republic, Denmark, Former Serbia and Montenegro, Ireland | |||
| Administrative Information | ||||
| NCT Number ICMJE | NCT00667810 | |||
| Other Study ID Numbers ICMJE | 3133K1-3000 B2521001 ( Other Identifier: Alias Study Number ) 2007-005994-79 ( EudraCT Number ) | |||
| Has Data Monitoring Committee | Yes | |||
| U.S. FDA-regulated Product | Not Provided | |||
| IPD Sharing Statement ICMJE | Not Provided | |||
| Responsible Party | Pfizer | |||
| Study Sponsor ICMJE | Pfizer | |||
| Collaborators ICMJE | Not Provided | |||
| Investigators ICMJE |
| |||
| PRS Account | Pfizer | |||
| Verification Date | December 2015 | |||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP | ||||